XML 64 R40.htm IDEA: XBRL DOCUMENT v3.20.4

Investments (Tables)

12 Months Ended

Dec. 31, 2020

Equity Method Investments and Joint Ventures [Abstract]

Schedule of Equity Method Investments

Equity Method Investments

A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows:

			Ownership interest						Carrying Amount
									December 31, 2020						December 31, 2019
Cronos Australia(i)			31%						$	—					$	(346)
Cronos GrowCo(ii)			50%						19,235						1,501
Natuera			50%						—						(598)
									$	19,235					$	557

(i)On October 25, 2019, Cronos Australia issued 40 million new shares in an initial public offering at an offering price of A$0.50 per share. The Company’s ownership in Cronos Australia decreased from 50% to 31% on November 7, 2019 when Cronos Australia began trading on the Australian Securities Exchange. This resulted in a reconsideration event, which required the reassessment of the Company’s variable interest entity conclusion. Upon reconsideration, the Company determined that the entity was no longer a variable interest entity as of December 31, 2019 and is now reported under the equity method.

(ii)On September 25, 2020, the Company and 2645485 Ontario Inc. (“Mucci”), the other joint venture partner of Cronos GrowCo, agreed to capitalize certain historical advances made by each shareholder to Cronos GrowCo. Total aggregate gross advances to Cronos GrowCo, excluding any amounts advanced by the Company to Cronos GrowCo under the GrowCo Credit Facility, were C$49,300 ($37,010), of which the Company advanced 50% and Mucci advanced the remaining 50% for an amount of C$24,650 ($18,505) each. As a result, the Company transferred the advances of C$24,650 ($18,505) to investments in equity accounted investees in respect of Cronos GrowCo.

The Company’s share of net earnings (losses) from equity investments accounted for under the equity method of accounting as of and for the years ended December 31:

			2020						2019						2018
Whistler Medicinal Marijuana Company (“Whistler”)(i)			$	—					$	29					$	178
Cronos Australia			(363)						(1,101)						(588)
Cronos GrowCo			(1,537)						(167)						(100)
MedMen Canada			—						35						(213)
Natuera(ii)			(2,610)						(805)						—
			$	(4,510)					$	(2,009)					$	(723)

(i)Whistler was incorporated in British Columbia, Canada and is a license holder under the Cannabis Act (Canada) with production facilities in British Columbia, Canada. The Company fully divested its investment in Whistler during 2019. See Note 7.

(ii)The Company’s share of accumulated net losses in excess of its equity investment in Natuera has been applied as a loss allowance on the loan receivable. See Note 8.

The following is a summary of financial information for the Company’s equity method investments as of and for the year ended December 31:

			2020						2019						2018
Current assets			$	19,126					$	23,200					$	7,121
Non-current assets			122,099						76,212						27,129
Current liabilities			24,223						52,796						3,746
Non-current liabilities			76,313						33,189						13,201
Revenue			367						52						5,344
Gross profit			(631)						—						—
Net loss			(11,453)						(2,048)						(874)

Schedule of Joint Ventures

Advances to Joint Ventures

			MedMen Canada(i)						Cronos GrowCo(ii)						Cronos Australia(iii)						Natuera						Total
As of January 1, 2020			$	471					$	18,966					$	—					$	—					$	19,437
Transfer to investments in equity accounted investees(ii)			—						(18,505)						—						—						(18,505)
Interest on advances			—						—						37						—						37
Advances to joint ventures recovered from (applied to) carrying amount of investments			—						—						(38)						—						(38)
Effect from foreign exchange			(4)						(461)						1						—						(464)
As of December 31, 2020			$	467					$	—					$	—					$	—					$	467

			MedMen Canada(i)						Cronos GrowCo(ii)						Cronos Australia(iii)						Natuera						Total
As of January 1, 2019			$	1,244					$	2,970					$	475					$	—					$	4,689
Advances (repayments)			(852)						15,494						274						219						15,135
Advances to joint ventures recovered from (applied to) carrying amount of investments			35						22						(779)						(224)						(946)
Effect from foreign exchange			44						480						30						5						559
As of December 31, 2019			$	471					$	18,966					$	—					$	—					$	19,437

(i)    Advance is unsecured, non-interest bearing, and there are no terms of repayment.

(ii)On September 25, 2020, the Company and Mucci agreed to capitalize historical advances made by each shareholder to Cronos GrowCo. The Company capitalized C$24,650 ($18,505) through a transfer of aggregate gross advances from advances to joint ventures to investments in equity accounted investees in respect of Cronos GrowCo. Refer to footnote (ii) to the first table set forth under Note 6(a).

(iii)A$1,500 is governed by an unsecured loan bearing interest at a rate of 12% per annum, calculated and compounded daily, in arrears, on the amounts advanced from the date of each advance. The loan is due on January 1, 2022. If the loan is overdue, the outstanding amount bears interest at an additional 2% per annum.

Schedule of Variable Interest Entities

The following is a summary of the maximum exposure to loss for the year ended December 31, 2020 and 2019:

			Ownership interest						Other Net Assets (Liabilities)						Maximum Exposure to Loss
Cronos Australia			31%						$	8,976					$	1,530
Cronos GrowCo			50%						109,329						21,125
MedMen Canada			50%						—						467
Natuera			50%						(6,849)						8,154
Balance as of December 31, 2020									$	111,456					$	31,276

			Ownership interest						Other Net Assets (Liabilities)						Maximum Exposure to Loss
Cronos Australia			31%						$	10,900					$	1,355
Cronos GrowCo			50%						3,091						20,700
MedMen Canada			50%						(199)						642
Natuera			50%						(358)						4,888
Balance as of December 31, 2019									$	13,434					$	27,585

X

- References

No definition available.

+ Details

Name:	us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of investments in and advances to affiliates. Does not include the tabular disclosure of the disaggregation of investments in and advances to affiliates across legal entities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 320
-Section S99
-Paragraph 6
-Subparagraph (SX 210.12-14)
-URI http://asc.fasb.org/extlink&oid=120401592&loc=d3e611322-123010

+ Details

Name:	us-gaap_InvestmentsInAndAdvancesToAffiliatesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685

+ Details

Name:	us-gaap_ScheduleOfVariableInterestEntitiesTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration